Ecological Effects of Decolonisation Strategies in Intensive Care
NCT02208154 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 8665
Last updated 2017-11-01
Summary
Previous research has shown that applying certain treatments can reduce both the number of infections and the presence of resistant bacteria in the intensive care (ICU) and its patients. These treatments have been used as standard care throughout the world for many years, but they have not been compared to each other yet. The investigators aim to evaluate the effect of 3 different treatments on the occurrence of resistant bacteria and bacterial infections in the ICU and to establish which treatment is the best.
All adult patients undergoing mechanical ventilation are eligible for this study and will receive treatment according to the study scheme. Twice weekly, sputum and rectal samples will be obtained to measure the effects.
All ICU-patients will receive standard treatment, consisting of daily body washing with an antiseptic (chlorhexidine 2%), oral care and a hand-hygiene program for health care workers as endorsed by the WHO. According to 4 different study periods, each participant will receive one of the following extra treatments depending on his or her admission date:
* Standard treatment only (this is the control group)
* Chlorhexidine 1% oral gel, this is an antiseptic.
* Antibiotic mouth paste containing 3 different antibiotics (selective oropharyngeal decontamination, SOD).
* Antibiotic mouth paste and suspension for the stomach and intestines containing 3 different antibiotics (selective digestive decontamination, SDD).
All treatments will be given 4 times daily with the purpose of killing harmful bacteria in the mouth (CHX, SOD,SDD) and digestive tract (SDD).
During the study the investigators will examine the effect of these treatments on:
* the occurrence of blood stream infections with certain bacteria
* cross-transmission of certain bacteria between patients
* presence of these bacteria in the respiratory tract of the patients
* patient survival
Benefits: Previous research has shown that these interventions can reduce infections in intensive care patients.
Risks: The interventions performed (both cultures and treatment) are considered safe and are already given as standard care in many ICUs throughout the world. There is a slight risk that bacteria become resistant to antibiotics: this will be monitored closely during the trial.
Conditions
- ICU-ecology (Multidrug Resistant Bacteria)
- ICU-acquired Bacteraemia
Interventions
- DRUG
-
Chlorhexidine oral care (CHX-Oro)
Oromucosal gel consisting of chlorhexidine 1%, administered 4 times daily.
- DRUG
-
Selective oropharyngeal decontamination (SOD)
SOD consists of application of a paste containing colistin, tobramycin in a 2% concentration and nystatin 1 x 10\^5 units. SOD will be applied to the mouth 4 times daily until extubation.
- DRUG
-
Selective Digestive Decontamination (SDD)
SDD consists of both: * SOD (described elsewhere) * AND 10 ml of an enteric suspension containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10\^6 i.u, to be administered via the nasogastric tube. The combination is administered 4 times daily (Unlike in previous studies, systemic antibiotics are not a part of SDD)
Sponsors & Collaborators
-
Paris 12 Val de Marne University
collaborator OTHER -
MJM Bonten
lead OTHER
Principal Investigators
-
Marc JM Bonten, Prof. · UMC Utrecht
-
Christian Brun-Buisson, Prof. · UPEC Paris
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-12-01
- Primary Completion
- 2017-10-27
- Completion
- 2017-10-27
Countries
- Belgium
- Italy
- Portugal
- Slovenia
- Spain
- United Kingdom
Study Locations
More Related Trials
-
Simplified Selective Digestive Tract Decontamination for the Prevention of Intensive Care Unit Acquired Infections
NCT01798537 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43
NCT01563263 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy of Mouth-rinse With Chlorhexidine for the Prevention of Ventilator-associated Infections in Intensive Care Unit
NCT04165356 ·Status: UNKNOWN ·Phase: NA
-
Impact of Teeth Brushing in Ventilated COVID-19 Patients.
NCT05575050 ·Status: COMPLETED ·Phase: NA
-
Detection of Chlorhexidine in Tracheal Secretions After Routine Oral Care With Chlorhexidine Gluconate
NCT02583321 ·Status: COMPLETED ·Phase: NA
-
Microbial and Pharmacological Assessment of Chlorhexidine
NCT03290105 ·Status: COMPLETED
-
Effectiveness of Chlorhexidine Wipe for Prevention of Multidrug-resistant Organisms in Intensive Care Unit Patients
NCT01989416 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Daily Bathing With Chlorhexidine in the Critical Patient
NCT02870062 ·Status: UNKNOWN ·Phase: PHASE1
-
Assessment of the Prevalence of Extended-Spectrum Betalactamase Producing Enterobacteriaceae Among ICU Staff
NCT02367339 ·Status: UNKNOWN
-
Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients
NCT07052604 ·Status: RECRUITING
-
Daily Chlorexidine Bath for Health Care Associated Infection Prevention
NCT05485051 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Dedicated Hygienist Staff on the Occurrence of Intensive Care Unit -Aquired Bloodstream Infections
NCT02891902 ·Status: COMPLETED
-
Characteristics of Lower Respiratory Tract Escherichia Coli Isolates in Mechanically Ventilated Intensive Care Patients
NCT03303937 ·Status: COMPLETED
-
The Impact of Chlorhexidine-Based Bathing on Nosocomial Infections
NCT00448942 ·Status: COMPLETED
-
About Oral and Gut Microbiota in Intensive Care Unit : SARS-CoV-2 (COVID-19) Infection Impact.
NCT04913142 ·Status: WITHDRAWN
-
Oral Care to Reduce Mouth and Throat Infections in Critically Ill Patients
NCT00078663 ·Status: COMPLETED ·Phase: PHASE3
-
4% Chlorhexidine Gluconate Daily Bathing for Prevention of Hospital-acquired Infections in Intensive Care Settings
NCT03639363 ·Status: COMPLETED ·Phase: PHASE4
-
Organosilane for Surface Cleaning in Intensive Care Units
NCT05673226 ·Status: COMPLETED ·Phase: NA
-
The Effect of Supraglottic and Oropharyngeal Decontamination on the Incidence of Ventilator-associated Pneumonia
NCT04325685 ·Status: COMPLETED ·Phase: NA
-
Impact of Antibio Prophylaxis on Occurence of Ventilator Associated Pneumonia in Trauma Patients
NCT07059039 ·Status: COMPLETED
-
Empiric Antibiotic Therapy for Ventilator-acquired Pneumonia With Gram-negative Bacilli in Intensive Care
NCT02127528 ·Status: UNKNOWN
-
Oropharyngeal and Nasopharyngeal Decontamination With Chlorhexidine Gluconate in the Reduction of the Postoperative Morbidity and Mortality After Major Pulmonary Resections
NCT01613365 ·Status: COMPLETED ·Phase: PHASE3
-
Antifungal Prophylaxis in Intensive Care Unit (ICU) Patients
NCT01495039 ·Status: COMPLETED ·Phase: PHASE4
-
Prehospital Ventilator-Associated Pneumonia Prevention Trial
NCT01902446 ·Status: COMPLETED
-
Direct E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia
NCT01042353 ·Status: COMPLETED ·Phase: PHASE4